New Large Shareholding Report Due to Affiliation with Samsung Pharmaceutical

The reporting person (㈜GemVax&Kael etc.) files a new large shareholding report for Samsung Pharmaceutical due to affiliate consolidation
㈜GemVax&Kael: Total assets KRW 158.875bn, liabilities KRW 101.646bn, equity KRW 57.229bn, largest shareholder (주)Gem&Company with 12.32%
㈜GLK Equity Invest: Total assets KRW 121.255bn, liabilities KRW 95.468bn, equity KRW 25.787bn, largest shareholder ㈜Ponylink with 100%
㈜Ponylink: Total assets KRW 287.706bn, liabilities KRW 71.609bn, equity KRW 216.097bn, largest shareholder ㈜GemVax&Kael with 21.75%
Acquisition funded by equity capital; acquisition price based on closing price on 2026.05.06
No disclosure of current holding ratio or change details (new report)